Bavarian Nordic A/S (CPSE: BAVA)
Health Care · Biotechnology · DK
Dkr209.40
+9.06% today · -12.3% 1Y
Bavarian Nordic A/S (CPSE: BAVA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.48B and employs 1,861 people.
Over the last twelve months the share price has lost 12.3%, trading between 171.30 and 244.80.
Tweenvest scores Bavarian Nordic A/S across four factors: quality 70/100, value 37/100, growth 83/100. Its strongest factor is growth.
BAVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.48B
- Revenue (TTM)
- $968.53M
- P/E
- 10.78
- EPS
- 14.84
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- Dkr244.80
- 52-week low
- Dkr171.30
- Avg volume (3M)
- —
- Shares outstanding
- 75.68M
- Employees
- 1,861
- Next earnings
- —
About Bavarian Nordic A/S
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
- ISIN
- DK0015998017
- Founded
- 1992
- Listed since
- Jan 3, 2000
- Exchange
- OMX Nordic Exchange Copenhagen
- Currency
- DKK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.